HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33
HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $37 to $33.
Share
Why It Matters
An expert still thinks ACAD is worth buying. But they lowered what they think the stock is worth. When experts lower their price targets, it means they see challenges ahead for the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.